Lupin Limited
↗Mumbai, India
Lupin Limited is an innovation-led, transnational pharmaceutical company headquartered in Mumbai, India that develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets. Founded in 1968 by Dr. Desh Bandhu Gupta with just INR 5,000 borrowed from his wife, Lupin has grown from a small vitamin manufacturer to become the 7th largest pharmaceutical company in India and the 4th largest generics pharmaceutical player by market capitalization globally. The company operates across the entire pharmaceutical value chain, spanning generic drugs (branded and complex generics), APIs, advanced drug delivery systems, and biotechnology including biosimilars. Lupin's portfolio addresses therapeutic areas including pediatrics, cardiovascular, anti-infectives, diabetology, asthma, anti-tuberculosis, and oncology across both developed and emerging markets.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Generic Pharmaceuticals, Biosimilars, Complex Injectables
SIZE & FINANCIALS
Employees:10000+
Revenue:$2.94B (trailing twelve months)
Founded:1968
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:N/A - Public company
Investors:Public shareholders on NSE/BSE
STOCK
Exchange:NSE, BSE
Ticker:LUPIN
Market Cap:$11.7B (as of March 2026)
PIPELINE
Stage:Multiple - Commercial to Phase 3
Lead Drug Stage:Armlupeg (Pegfilgrastim biosimilar) - FDA approved December 2025; Ranibizumab (LUBT010) - Phase 3 completed, EMA submission; Risperidone LAI - FDA approved September 2025
Modalities:Small molecule, Biosimilars, Complex Injectables, Inhalation, Long-acting injectables, Generic formulations, APIs
Trial Phases:Phase 3: 2
FDA Approvals:277
CORPORATE STRUCTURE
Subsidiaries:Lupin Pharmaceuticals Inc. (USA, Baltimore, MD) - $891M enterprise, Lupin USA Inc., Lupin pharma Canada Ltd, Multiple subsidiaries in Mexico, Brazil, Netherlands, Japan
Key Partnerships:Valorum Biologics (US commercial rights for Armlupeg pegfilgrastim biosimilar), Mylan (Enbrel/Etanercept biosimilar commercialization), Nanomi B.V. (long-acting injectable platform technology), Multiple collaborations for biosimilar development
COMPETITION
Position:Leader - 3rd largest in US generics by prescriptions, 4th globally in generics by market cap, strong biosimilars player
Competitors:Teva Pharmaceutical Industries, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, Aurobindo Pharma, Zydus Cadila, Mylan/Viatris, Sandoz +4 more
LEADERSHIP
Key Executives:
Vinita D. Gupta - CEO & Executive Director
Manju D. Gupta - Chairman (Non-Executive)
Nilesh Deshbandhu Gupta - Managing Director & Executive Director
Ramesh Swaminathan - Executive Director, Global CFO, CRO & Head of API Plus SBU
Christoph Funke - Chief Technical Operations Officer
Dr. Shahin Fesharaki - President - Global Chief Scientific Officer
Dr. Sofia Mumtaz - President of Legal and Compliance (Australia, Japan & Canada)
Dr. Ranjana Pathak - Chief Quality Officer
Jim Loerop - Chief Corporate Development Officer
Scientific Founders:Dr. Desh Bandhu Gupta (1968-2017) - Founder, former professor of chemistry at BITS-Pilani
Board Members:Manju D. Gupta - Chairman, Vinita D. Gupta - CEO & Executive Director, Nilesh D. Gupta - MD & Executive Director, Jeffrey Kindler - Independent Director (CEO Centrexion Therapeutics, Senior Advisor Blackstone), Alfonso Zulueta - Independent Director (30+ years Eli Lilly, held VP Global Marketing & President roles)
LINKS
Website:lupin.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Lupin Limited and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Lupin Limited. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.